Detalhe da pesquisa
1.
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Br J Haematol
; 201(6): 1116-1124, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004981
2.
Treatment-free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5-year analysis of DASFREE.
Br J Haematol
; 202(5): 942-952, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37246588
3.
Dasatinib plus Peg-Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA-PegIFN study).
Br J Haematol
; 200(2): 175-186, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36214090
4.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
N Engl J Med
; 381(24): 2315-2326, 2019 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31826340
5.
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica
; 107(12): 2859-2869, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35615931
6.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol
; 194(2): 393-402, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34195988
7.
Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response.
Value Health
; 24(5): 683-690, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933237
8.
Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years.
Br J Haematol
; 189(3): 452-468, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072631
9.
Novel analytical methods to interpret large sequencing data from small sample sizes.
Hum Genomics
; 13(1): 41, 2019 08 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31470908
10.
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Cancer
; 125(16): 2818-2828, 2019 08 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31034603
11.
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol
; 204(4): 1536-1539, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38323384
12.
Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome.
Br J Haematol
; 187(3): 337-346, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31271217
13.
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Blood
; 129(7): 846-854, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-27932374
14.
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia.
Haematologica
; 104(6): 1150-1155, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30573507
15.
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Ann Hematol
; 98(5): 1159-1168, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-30798348
16.
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Ann Intern Med
; 168(7): 461-470, 2018 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29459949
17.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
Lancet Oncol
; 19(6): 747-757, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29735299
18.
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
Cancer
; 124(14): 2956-2963, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29723417
19.
How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.
Br J Haematol
; 180(1): 24-32, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29048128
20.
MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.
BMC Cancer
; 18(1): 1098, 2018 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30419846